Loading
A phase 2 trial of Azacitidine in acute myeloid leukaemia, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission is a phase 2 interventional study registered as NCT05197426 by Bristol-Myers Squibb, with 19 participants enrolled, started 2022-01-17 and due to reach its primary completion in 2025-01-27. Interventions recorded: Oral Azacitidine. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
19 enrolled.
Insufficient number of participants with events to calculate via KM methodology; Figures from the ClinicalTrials.gov results section (first posted 2026-02-11), not from a publication · range 1.4 to NA
SourceInsufficient number of participants with events to calculate via KM methodology; Figures from the ClinicalTrials.gov results section (first posted 2026-02-11), not from a publication · range 12.3 to NA
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Recurrence Free Survival (RFS)primary | Treatment 1 | 12 | Insufficient number of participants with events to calculate via KM methodology; Figures from the ClinicalTrials.gov results section (first posted 2026-02-11), not from a publication | - | - | link |
| Treatment 2 | 7 | 7.4 months | ||||
| Overall Survival (OS) | Treatment 1 | 12 | Insufficient number of participants with events to calculate via KM methodology; Figures from the ClinicalTrials.gov results section (first posted 2026-02-11), not from a publication | - | - | link |
| Treatment 2 | 7 | 15.1 months |
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Bristol Myers Squibb, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy and the tag pipeline.
Shares Bristol Myers Squibb, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy and the tag pipeline.